What it sells
Noninvasive neuromodulation
Business model breakdown
Buyer: who owns the budget?
UnverifiedHospital ICU and neurocritical care leadership / value-analysis committees (ICU cost burden is the stated pitch).
Trigger: what makes them buy now?
ICU cost burden of $254B (1% of US GDP); inflammation drives complications and excess costs, with high-cost patients being 10% of patients and consuming 50% of resources.
Economics: what it saves and how it charges
Medical device to be sold to hospitals on outcome and cost-of-care value; claims randomized pilot studies showed improved outcomes, shorter length of stay and lower cost (results unpublished); pre-commercial.
Distribution: how it reaches customers
UnverifiedPre-commercial clinical-stage; direct hospital sales expected after regulatory clearance.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-28 | Seed | $5.7M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.